Next Article in Journal
Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis
Next Article in Special Issue
hCG: Biological Functions and Clinical Applications
Previous Article in Journal
Autophagy and Inflammatory Response in the Tumor Microenvironment
Previous Article in Special Issue
Human Chorionic Gonadotropin and Breast Cancer
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2017, 18(9), 2014; doi:10.3390/ijms18092014

Human Chorionic Gonadotrophin as a Possible Mediator of Leiomyoma Growth during Pregnancy: Molecular Mechanisms

1
Centro Scienze Natalità, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
2
Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
3
Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico AND Università degli Studi di Milano, 20122 Milan, Italy
*
Author to whom correspondence should be addressed.
Received: 29 August 2017 / Revised: 12 September 2017 / Accepted: 13 September 2017 / Published: 20 September 2017
(This article belongs to the Special Issue hCG—An Endocrine, Regulator of Gestation and Cancer)
View Full-Text   |   Download PDF [1720 KB, uploaded 20 September 2017]   |  

Abstract

Uterine fibroids are the most common gynecologic benign tumors. Studies supporting a strong pregnancy-related growth of leiomyomas generally claimed a crucial role of sex steroid hormones. However, sex steroids are unlikely the unique actors involved as estrogen and progesterone achieve a pick serum concentration in the last trimester while leiomyomas show a typical increase during the first trimester. Given the rapid exponential raise in serum human Chorionic Gonadotrophin (hCG) at the beginning of gestation, we conducted a review to assess the potential role of hCG in the striking growth of leiomyomas during initial pregnancy. Fibroid growth during initial pregnancy seems to correlate to the similar increase of serum hCG levels until 12 weeks of gestation. The presence of functional Luteinizing Hormone/human Chorionic Gonadotropin (LH/hCG) receptors was demonstrated on leiomyomas. In vitro treatment of leiomyoma cells with hCG determines an up to 500% increase in cell number after three days. Expression of cyclin E and cyclin-dependent kinase 1 was significantly increased in leiomyoma cells by hCG treatment. Moreover, upon binding to the receptor, hCG stimulates prolactin secretion in leiomyoma cells, promoting cell proliferation via the mitogen-activated protein kinase cascade. Fibroid enlargement during initial pregnancy may be regulated by serum hCG. View Full-Text
Keywords: human chorionic gonadotropin; fibroid; leiomyoma; estrogen; progesterone human chorionic gonadotropin; fibroid; leiomyoma; estrogen; progesterone
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Sarais, V.; Cermisoni, G.C.; Schimberni, M.; Alteri, A.; Papaleo, E.; Somigliana, E.; Vigano’, P. Human Chorionic Gonadotrophin as a Possible Mediator of Leiomyoma Growth during Pregnancy: Molecular Mechanisms. Int. J. Mol. Sci. 2017, 18, 2014.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top